Spondyloarthritis & psoriatic arthritis
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
Authors' conclusion
Bimekizumab, a dual-IL-17A/F inhibitor, may confer protective effects for uveitis in patients with axSpA.
Study context
- Population
- Patients with axial spondyloarthritis (axSpA) (nr-axSpA and r-axSpA) in the BE MOBILE 1 and 2 and BE AGILE trials and their open-label extension (OLEs)phase 2b/3 pool N=848
- Participants
- 349 vs 237
- Comparison
- Bimekizumab 160 mg vs placebo
- Bimekizumab (BKZ)n = 349
- Placebon = 237reference
- Outcome
- Uveitis rates and EAIR/100 PYs
- Follow-up
- Double-blind treatment period
Methodological detailsdouble-blind treatment period, placebo-controlled, open-label extension pool
- Double-blind treatment period
- Placebo-controlled
- Open-label extension pool
Pooled result
As reported in the abstract
Uveitis, BE MOBILE 1 and 2 double-blind period
| Group | Value | Exposure-adjusted incidence rates (EAIR)/100 patient-years (PYs) (95% CI) |
|---|---|---|
| BKZ | 0.6% | 1.8 (0.2 to 6.7) |
| Placebo | 4.6% | 15.4 (7.7 to 27.5) |
Value
BKZ0.6%
Placebo4.6%
Exposure-adjusted incidence rates (EAIR)/100 patient-years (PYs) (95% CI)
BKZ1.8 (0.2 to 6.7)
Placebo15.4 (7.7 to 27.5)
- BKZ vs Placebo: nominal p=0.001
Further pooled results
Uveitis in patients with history of uveitis (subgroup) · double-blind treatment period
nominal p=0.004
EAIR/100 PYs (95% CI) BKZ 6.2 (0.2 to 34.8) · Placebo 70.4 (32.2 to 133.7)
- Uveitis EAIR, phase 2b/3 pool (≥1 BKZ dose, incl. OLEs)
- 1.2 · EAIR · 95% CI 0.8–1.8 · /100 PYs
- Uveitis EAIR, phase 2b/3 pool (≥1 BKZ dose, incl. OLEs): N=848
Original publication
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Ann Rheum Dis. Published 14 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →